Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Little House Capital LLC

Little House Capital LLC trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 9.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 13,723 shares of the biopharmaceutical company’s stock after selling 1,475 shares during the quarter. Little House Capital LLC’s holdings in Bristol-Myers Squibb were worth $704,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Intellectus Partners LLC lifted its stake in Bristol-Myers Squibb by 1.5% during the 4th quarter. Intellectus Partners LLC now owns 37,726 shares of the biopharmaceutical company’s stock valued at $1,936,000 after acquiring an additional 574 shares during the period. Financial Advisors LLC lifted its stake in Bristol-Myers Squibb by 15.1% during the 4th quarter. Financial Advisors LLC now owns 3,979 shares of the biopharmaceutical company’s stock valued at $204,000 after acquiring an additional 522 shares during the period. Stonebrook Private Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $1,088,000. PGGM Investments acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $5,049,000. Finally, Opinicus Capital Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $425,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMY has been the subject of several analyst reports. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday. Finally, Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded up $0.15 during trading hours on Friday, reaching $44.85. 21,281,927 shares of the company’s stock were exchanged, compared to its average volume of 12,141,314. Bristol-Myers Squibb has a 1 year low of $44.34 and a 1 year high of $69.10. The company has a market capitalization of $90.90 billion, a P/E ratio of -14.47, a price-to-earnings-growth ratio of 16.31 and a beta of 0.39. The business has a fifty day moving average of $51.03 and a two-hundred day moving average of $51.14. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 50.04%. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the firm earned $2.05 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, research analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.35%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.